Condition
Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Not Yet Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT07079410Phase 2Not Yet Recruiting
Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
NCT06728618Phase 2Not Yet Recruiting
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
Showing all 2 trials